title: JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers.
authors.forename: C
authors.initials: C
authors.lastname: Vicente
authors.forename: I
authors.initials: I
authors.lastname: Vázquez
authors.forename: N
authors.initials: N
authors.lastname: Marcotegui
authors.forename: A
authors.initials: A
authors.lastname: Conchillo
authors.forename: C
authors.initials: C
authors.lastname: Carranza
authors.forename: G
authors.initials: G
authors.lastname: Rivell
authors.forename: E
authors.initials: E
authors.lastname: Bandrés
authors.forename: I
authors.initials: I
authors.lastname: Cristobal
authors.forename: I
authors.initials: I
authors.lastname: Lahortiga
authors.forename: M J
authors.initials: MJ
authors.lastname: Calasanz
authors.forename: M D
authors.initials: MD
authors.lastname: Odero
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D005260:Female; D005819:Genetic Markers; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics* / Q000502:physiology*; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D008957:Models, Genetic; D009154:Mutation; D011379:Prognosis; D012306:Risk; D013997:Time Factors
chemical_list: D005819:Genetic Markers; D053614:Janus Kinase 2